Moderna (MRNA) Stock: Buy, Sell, or Hold?
MRNA - Moderna, Inc. Common Stock
$182.56
9.62 (5.56%)
▲
5d:
+26.98%
30d:
+25.79%
90d:
+199.28%
WAIT
LOW Confidence
Analysis Updated: Sep 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MRNA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MRNA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $182.56, which is considered extended relative to its 30-day fair value range of $110.37 to $169.02.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is approaching resistance at $187.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: MRNA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $119.56. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is approaching resistance at $187.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: MRNA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $119.56. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$110.37 -
$169.02
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
15.8%
Protect Your Profits
MRNA is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+8.0% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BEARISH: Trading 34.5% above Wall St target ($119.56)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$110.37 -
$169.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$130.38
Resistance Level
$187.20
Current Trend
Strong Uptrend
Technical data as of
Sep 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-38.14
Wall Street Target
$119.56
(-34.5%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
-85.1%
Profit Margin
-141.4%
Share & Embed Analysis
Last updated: September 22, 2026 9:38 PM ET
Data refreshes hourly during market hours. Next update: 10:38 PM
Data refreshes hourly during market hours. Next update: 10:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 60 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 51 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 63 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 63 BUY |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
